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Abstract
Ovarian cancer is the eighth most commonly occurring cancer in women. Clinically, the limitation of conventional
screening and monitoring approaches inhibits high throughput analysis of the tumor molecular markers toward
prediction of treatment response. Recently, analysis of liquid biopsies including circulating tumor DNA (ctDNA)
open new way toward cancer diagnosis and treatment in a personalized manner in various types of solid tumors. In
the case of ovarian carcinoma, growing pre-clinical and clinical studies underscored promising application of ctDNA
in diagnosis, prognosis, and prediction of treatment response. In this review, we accumulate and highlight recent
molecular findings of ctDNA analysis and its associations with treatment response and patient outcome.
Additionally, we discussed the potential application of ctDNA in the personalized treatment of ovarian carcinoma.
Keywords: Ovarian cancer, Circulating tumor DNA, Prognosis
Introduction
Ovarian cancer was reported with the highest mortality
rate (almost 50% of new cases are annually reported by
the American cancer society) among the gynecologic
malignancies [1]. Most of ovarian cancer patients are di-
agnosed at the advanced stages, at which the tumors
have disseminated. Depending on the stages of the dis-
ease, the treatment approach may consist of surgery,
chemo, radiation, hormone or targeted therapy toward
shrinkage and the elimination of the primary tumor and
also suppression of the metastatic progression [2]. Clin-
ically, response to standard of the treatment regimens is
vary among the patients due to the complexity of dis-
ease, particularly cellular and molecular heterogeneities
of tumor. Therefore, the prediction of the treatment effi-
cacy at early stages of therapy can enhance the accuracy
of the patient’s selection toward the administration of
appropriate treatment regimens, and particularly chemo-
therapy [2]. Although implementation of liquid biopsy
approaches improved the patient outcome in various
types of cancers including lung and breast in a personal-
ized manner, in the case of ovarian cancer, utilizing an
appropriate approach to identify the proper treatment
for the specific patient is the matter of debate [3]. Ac-
cordingly, to tackle this problem, more studies must be
performed to identify the biomarkers responsible for pa-
tient response to chemotherapies such as CA125 (Can-
cer Antigen 125) level [4] or human epididymis protein
4 (HE4) [5]. However, the accuracy and effectiveness of
these biomarkers on the prediction of the chemotherapy
response differ among the patients with various epi-
demic and clinical features [6]. Genomic profiling of tis-
sue biopsy provides a snapshot of the dynamic behavior
of tumor information and uncovers the genomic
characterization of the tumor at the time of diagnosis
[7]. Also, these challenges are particularly obvious in the
patients who are resistant to therapy or in the patient’s
follow up [8]. In recent years, identification and
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characterization of cancer-derived components such as
circulating tumor cells (CTC), exosomes, and circulating
tumor DNA (ctDNA) known as liquid biopsy [8, 9],
opened a new way in the patients’ stratification and per-
sonalized treatment [7]. Of these, the detection of
ctDNA tumor-specific mutations show a great promise
in the patient’s selection and precision medicine, and be-
sides, it can be suggested as a prognostic factor for the
prediction of treatment response across several tumor
types including lung, breast, colorectal, and melanoma
cancers [9]. The previous review articles have reported
the technological aspects of both detection and isolation
of CTC alongside ctDNA as a diagnostic marker in ovar-
ian cancer [10, 11]. While the present review, aim to
consider mainly the clinical application of ctDNA in
treatment and management of ovarian cancer patients.
Moreover, the current review presents studies that com-
pare genetic and molecular changes in ctDNA with tis-
sues in ovarian cancer patients. The potential
application of ctDNA as a prognostic factor for the pre-
diction of the patient outcome in ovarian cancer also
will be discussed.
The current challenge in the treatment of ovarian cancer
Understanding the molecular mechanisms of ovarian
cancer, as a heterogeneous disease and underlying treat-
ment resistance, can lead to discovery of some new
therapeutic agents [12]. The standard of care treatment
approaches for advance ovarian cancer is relaying on a
primary cytoreductive surgery. Accordingly, it can be
followed using an adjuvant therapy based on various
chemotherapy-accompanied with the combination ther-
apies regimens, which can improve response and the pa-
tients overall survival (OS) [13]. Unfortunately,
chemotherapy resistance at the cancer advanced-stage is
an important clinical challenge [14]. To date, several
mechanisms of drug resistance have been explored, in-
cluding inactivation of the p53 pathway [15], genome
wide mutations [16], the enhanced expression of anti-
apoptotic genes [17], epigenetic changes [18], dysfunc-
tionality of DNA repair pathways [19], diminished drug
accumulation [20], and the elevated drug inactivation
[21]. In this regard, all these mechanisms lead to gen-
omic instability, which allows cancer cells to adapt and
survive against chemotherapy [22]. Beside these mecha-
nisms, a particular role of cancer stem cells (CSCs)
clones are defined within tumor microenvironment
(TME) [23] and tumor-associated mesenchymal stem
cells [24]. Also it has been observed that, CSCs have an
appositive association with platinum, carboplatin, and
paclitaxel resistance at the advanced-stage of ovarian
cancer. In addition, the TME features including immune
cell infiltration, angiogenesis, and hypoxia have been im-
plicated in the platinum chemoresistance [25].
Furthermore, the investigation of molecular ovarian can-
cer tissue signature has paved the new way for bio-
marker discovery to assist the clinicians in making better
treatment decisions. In this regard, a large number of
clinical and preclinical studies suggested potential of
tissue-based transcriptomics and proteomics biomarker
information for the chemo-resistance prediction [26].
Meanwhile, pre-mediated cellular mechanisms such as
clinical phenotypes, chaperones, metabolic proteins,
transcription regulators, transporters, and cytoskeletal
proteins are up-regulated in the patients with chemo-
resistance. Although tissue biopsy is a gold standard to
assess the pathological feature of disease, a recently li-
quid biopsy presented various advantages over this con-
ventional approach [27]. The analysis and role of blood-
based biomarker for evaluating the patient response to
chemotherapy are undeniable [13]. Also, the plasma-
derived ctDNA is the most commonly candidate in clin-
ical practice due to its abundance and overcome on the
isolation challenges [28]. The use of ctDNA in monitor-
ing the patients with cancer prevents the risks associated
with the repeated tissue biopsies [29].
The current prognostic biomarkers in the prediction of
treatment response in ovarian cancer
Lack of an appropriate approach in chemotherapy re-
sponse prediction in ovarian cancer is likely leading to
poor patient’s survival [30]. CA125, which is expressed by
epithelial ovarian tumors and other tissues of mullerian
origin, was the first ovarian cancer biomarker described
by Rober Bast et al. Accordingly, increase in the serum
level of CA125 is observed in diverse malignancies, men-
struation or pregnancy, and benign gynecological condi-
tions [31]. The measurement of serum CA125, as a vital
biomarker in clinical practice, was applied for screening
high risk women, and also to predict clinical course and
response to chemotherapy. In fact, dynamic changes in
serum CA125 levels as a chemo responsiveness predictor
can also be used to predict the response to the first-line
and the second-line chemotherapy. However, the clinical
value of CA125 is uncertain due to its limitations. For in-
stance; it has been evidenced that, CA125 level is not ele-
vated in 50% of the stage I women and in 30% of more
advanced ones [32].
HE4 (Human Epididymis Protein 4) is overexpressed
in ovarian cancer. Also, the combination of CA-125 and
HE4 have the highest sensitivity and specificity in pa-
tients sera and also helps in the prediction of malignancy
[33]. In addition, it is important to consider its potential
false-positive results with CA 125 [34].
Ova1 measures five proteins named as CA-125, trans-
thyretin, apolipoprotein A1, beta-2 microglobulin, and
transferrin with the FDA approval [35]. Vascular Endo-
thelial Growth Factor (VEGF) is a glycosylated
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angiogenesis mediator, which is independently associ-
ated with a shorter OS and disease-free survival. Not-
ably, the combination of VEGF with CA-125 and HE4
increased the diagnostic sensitivity up to 84% at the
stage I [36].
Kallikreins (KLKs) with 15 family members are re-
sponsible in cell growth, angiogenesis, invasion, and me-
tastasis [37]. The decreased incidences of high “false
negative” rates were also found in the HE4 and CA-125
positive patients [38].
Osteopontin (OPN) is a secreted extracellular matrix
glycoprotein, which is involved in wound healing, the
immune response, inflammation, tumorigenesis, bone
remodeling, and apoptosis inhibition [39].
Mesothelin is a cell surface glycoprotein that are im-
portant in tumor metastasis, cancer cell survival, prolif-
eration, and drug resistance [40]. Also, Mclntosh et al.
detected the increased level of serum mesothelin in 60%
of ovarian cancer patients with 98% specificity. So, a
combination of mesothelin and CA-125 was suggested
[41]. Additionally, Obulhasim et al. found that, mesothe-
lin is expressed in 100% of serous cystadenocarcinoma
as well as serous borderline ovarian tumor [42].
In addition to these biomarkers, few prognostic bio-
markers were introduced as valuable indicators including
macrophage colony-stimulating factor (M-CSF), bikunin,
EphA2, Transthyretin (TTR), Transferrin receptor 1, B7-
H4, Prostasin, and soluble EGF receptor [43–51]
(Table 1).
Circulating tumor DNA (ctDNA)
Liquid biopsy is a minimally invasive approach, which
can be applied for the detection of molecular biomarkers
from body fluids with no need for the costly or invasive
procedures [90]. Accordingly, it is considered as a simple
and non-invasive alternative to surgical biopsies, which
enables discovering a wide range of information on a
disease or a tumor through a simple blood sample. Not-
ably, new dedicated methods allow us screening and
monitoring cancer cell through circulating tumor cells
(CTCs) and extracellular mirco-vesicles (including exo-
somes) containing small-RNA, mRNA, and ctDNA [91].
Tumor-associated genetic alterations can elucidate the
molecular stratification of tumors toward the identifica-
tion and selection of an appropriate targeted treatment.
Historically, the presence of ctDNA in the blood of the
patients with cancer was firstly recognized in the 1970s
[92]. The elevated level of ctDNA is observed at the ad-
vanced stage of the disease progression, partly due to the
reduced DNase activity [93]. Besides, ctDNA can reflect
some specific genomic alterations of the tumor origin in-
cluding mutations, methylation, and copy number varia-
tions (CNVs) [94] and preserving the genetic
characteristics of the original tissue [95] (Fig. 1). The
ctDNA-based mutation detection was also reported in
82% of the metastatic patients and 52% of the patients
with localized disease [96]. Importantly, 95% concord-
ance in mutational status was found between ctDNA
and matched tumor tissue, which suggest that, the ana-
lysis of ctDNA, as a non-invasive approach, not only al-
lows the tumor characterization and resolves the
complexities of conventional tissue biopsy, but it also
acts as an indicator for monitoring the treatment re-
sponse in a given therapy [97]. A reliable biomarker can
ensure that, which patients are more likely to relapse
after receiving the adjuvant therapy [98]. Also, usage of
ctDNA monitoring for a successful treatment over the
resistance was reported in several clinical trials [99, 100].
Moreover, an invasive conventional tumor biopsy cannot
be performed, while the frequent imaging can increase
the risk of radiation exposure. Thus, the minimally inva-
sive tests can be frequently repeated in a time series
framework, which provide constant updates of tumor
genetic composition and mutations, suggesting the best
course of treatment at an appropriate time [101].
Tumor tissue-based mutations versus ctDNA mutations in
ovarian cancer
Over the last few years, genome-wide analysis revealed
numerous alterations in ovarian cancer genomes includ-
ing the inactivation of mutations in tumor suppressor
genes such as TP53, BRCA1, BRCA2, PTEN, and RB1;
and in a SWI/SNF chromatin remodeling gene, ARID1A
[102, 103]. Other studies have detected the activation of
mutations in the oncogenes KRAS, PIK3CA, BRAF, and
ERBB2 [102, 104–106]. In fact, identifying the common
gene mutation in blood rather than tissue, can be helpful
in determining the patients whom benefit from therapy
using the existing molecular targeting drugs. In this re-
gard, Morikawa et al., [107] using the droplet digital
PCR (ddPCR) detected PIK3CA-H1047R and KRASG12D
mutations in tumor tissue and also matched ctDNA of
33 patients with ovarian clear cell carcinoma and then
monitored their response to therapy. Accordingly, they
highlighted the detection of mutations in ctDNA as a
powerful tool for the diagnosis of ovarian clear cell car-
cinoma and for predicting its recurrence. In addition to
this, Ogasawara et al. [108] assessed the PIK3CA and
KRAS mutations in tumor and ctDNA of 304 patients
with ovarian cancer. In addition, they indicated that, the
detection rates of PIK3CA and/or KRAS ctDNA muta-
tions were associated with the advanced stage; however,
they were not related to the histologic subtype or re-
sidual tumor status. ctDNA detection was also associ-
ated with the shorter progress free survival (PFS) and
the increased risk of recurrence independently [108]. In
a pre-clinical study, the somatic mutation status of the
TP53 was evaluated in both patient-derived tumor
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specimens and corresponding ctDNA, which resulted
into the detection of similar hotspot mutation in TP53
in both sources of biopsy [109]. Moreover, Yong-Man
Kim et al. [110] assessed the TP53 mutations across 103
tumor tissues from 61 patients with a high grade ovarian
cancer and also confirmed TP53 mutations in 41 pa-
tients. They concluded that, detection of TP53 mutation
in ctDNA is a potential tumor-specific biomarker for the
Table 1 List of known biomarkers in prediction of ovarian cancer treatment response
Biomarkers utility Weakness
CA125 Can be assessed in epithelial, endometrial and clear cell types in
patients with clinical stage I- IV [52].
• Cannot be elevated in some ovarian cancer patients.
• Can be elevated in healthy premenopausal women during
menses, in pregnancy, in nonmalignant gynecologic diseases,
such as ovarian cysts, endometriosis, adenomyosis, and uterine
leiomyomas, in several nonmalignant nongynecological
diseases, such as peritoneal, pleural, and musculoskeletal
inflammatory disorders as well as pelvic inflammatory disease,
liver, and renal as well as cardiac disease and in most types of
advanced adenocarcinomas, including breast, colorectal,
pancreas, lung, endometrium, and cervix as false positive.
• Is not expressed in pure mucinous tumors [53].
HE4 Can be assessed in epithelial ovarian adenocarcinomas high [54]. • Can be elevated in endometrioid and clear cell histology [55].
• Cannot be detected in epithelial/ nonepithelial ovarian cancer,
including sex cord stromal tumors and germ cell tumors [54]
• Overexpressed in gastric cancer, pancreatic cancer as well as
occasionally in colon and hepatocellular cancer [56, 57].
Ova1 Ova1 score≥ 5 in premenopausal women and≤ 5
postmenopausal ones were detected, and was considered with
higher risk of malignancy [58].
• Ova1 demonstrated 92.5% sensitivity, but lower specificity of
42.8% [58]
VEGF VEGF level was independently associated with shorter disease-free
survival and overall survival [59].
• Can be compared with traditional biomarkers, such as CA125
and HE4 moderately [60].
• It must be combined with CA-125 and HE4 to increase the diag-
nostic sensitivity up to 84% in stage I [36].
• Can be elevated in various cancers, including colorectal, [61],
lung [62], gastric [63], endometrial [64] and breast cancer [65].
Kallikreins Level more than 4.4 mg/L indicated poor prognosis in patients
[66].
• Exhibit low sensitivity in the early detection of ovarian cancer.
• It must be combined with CA-125 for higher specificity and sen-
sitivity [67].
Osteopontin Has a sensitivity of 83.3% in the detection of ovarian cancer [68]. • Its specificity is low.
• It must be combined with CA-125 for higher sensitivity [69].
Mesothelin Elevate in patients with ovarian cancer compared with normal
healthy [70].
• Is not useful markers for early detection [71].
M-CSF Elevated levels of M-CSF1 in serum and ascites are associated with
a poor prognosis [72]. Serum M-CSF appears to improve the diag-
nostic reliability of serum CA 125 alone [73].
• This biomarker expressed also in other cancers [74].
Bikunin Mediates suppression of tumor cell invasion and metastasis.
Low expression is associated with late-stage disease.
Low response to chemotherapy, and reduced survival time [44].
• Bikunin is present predominantly in amniotic fluid and urine of
healthy individuals [75].
EphA2 Overexpression is associated with poor prognosis [45]. • EphA2 is overexpressed in many human cancers [76, 77].
Transthyretin Efficient serum marker for the diagnosis [47]. • Plasma levels, affected by acute and chronic diseases.
• Its usage must be considerate [78].
Transferrin
receptor 1
Overexpression in high-grade tumor tissues [79]. • Overexpressed in several cancers [80–82].
B7-H4 Over expression can be used as a tumor marker with negative
prognostic effect for epithelial cell ovarian cancer potential
immunotherapeutic target [83].
• B7-H4 is highly expressed in various human tumors, including
breast, ovarian, lung, pancreatic, gastric and urothelial cell car-
cinoma [84, 85].
Prostasin Overexpress in ovarian cancer patients at levels significantly higher
than normal controls [50].
• Many human cancers show unusual expression of prostasin like




Is associated with less favorable disease outcomes [88]. • Little or no difference to survival, either as maintenance
treatment after first-line chemotherapy or in association with
chemotherapy in recurrent cancer [89].
Abbreviations: CA125 cancer antigen 125, HE4 human epididymis secretory protein 4, VEGF vascular endothelial growth factor, M-CSF macrophage colony
stimulating factor, EphA2 ephrin type-A receptor 2, B7-H4 a molecule of B7 family
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treatment response monitoring [110]. Clinically, a copy
number abnormality was reported in 20% of the patients
with ovarian cancer [111] including claudin 4 (CLDN4),
RAS oncogene family (RAB25), and ATP binding cas-
sette subfamily F member 2 (ABCF2) [112, 113]. Hong
No et al. [114] reported the lack of positive association
between mutation in these genes at ctDNA level with
the disease-free survival (DFS) and OS [114]. Moreover,
BRCA1 and BRCA2 play pivotal roles in DNA repair and
germline mutations [115]. Additionally, these BRCA1/2
reversion mutations could be detected by ctDNA se-
quencing analysis in the patients who received platinum
and/or PARP inhibitors [116]. Rebecca et al. [117] com-
pared the genetic variants of a panel of 50 genes between
tumor and ctDNA among 20 patients diagnosed with
the high-grade ovarian carcinoma during neoadjuvant
chemotherapy (NACT). Notably, 38 genetic variants out
of six genes (TP53, KIT, KDR, KRAS, PIK3CA, and
PTEN) were identified in tumors pre-NACT, while 59
variants out of 19 genes were detected in the ctDNA. In
this study, targeted NGS determined the increased level
of ctDNA variants with a minimal overlap between
ctDNA and tumor DNA. Most of the mutations found
in ctDNA were not present in tumor resulting from the
amplifying of ctDNA. Besides, the heterogeneity in the
tumor can be detected in ctDNA, in contrast with tumor
tissue [117].
The potential application of ctDNA to the management of
treatment response in ovarian cancer
To date, FDA has not approved any ctDNA-related test
in ovarian cancer. In this regard, a clinical ctDNA
Fig. 1 ctDNA isolation and application in the ovarian cancer patient
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workflow was recently designed in the management of
the high-grade ovarian cancer, to investigate the clinic-
ally actionable alterations of 500 cancer-related genes,
which was performed in 12 patients. In seven patients, a
good concordance of mutations and copy number alter-
ations in ctDNA and tumor samples (NF1, RAD51C,
PTEN, BRCA2, STAG2, FANCA, CDKN1B, ERBB2,
ERBB4, and MAP 2 K1), and also alterations associated
Table 2 Studies of ctDNA in ovarian cancer patients related to treatment response monitoring
References year No of
patients
Identified Abnormalities Methodology
Gifford et al. [121] 2004 138 hMLH1 methylation Microsatellite PCR
Swisher et al. [122] 2005 137 p53 mutation DNA sequencing
Kamat et al. [123] 2006 – Level RT-PCR
Capizzi et al. [124] 2008 22 Level RT-PCR
Kamat et al. [125] 2010 164 Beta-globin RT-PCR
Wimberger et al. [126] 2011 62 Fluorimetry Fluorescence
Forshew et al. [127] 2012 38 TP53. Other markers include PTEN, BRAF, KRAS, EGFR, PIK3CA TAm-Seq, dPCR
Murtaza et al. [128] 2013 3 RB1, ZEB2, BUB1, CES4A, MTOR, PARP8 NGS, qPCR
Choudhuri et al. [129] 2014 100 Level RT-PCR
Martignetti et al. [130] 2014 1 FGFR2 fusion transcript RT-PCR
Pereira et al. [131] 2015 22 TP53, PTEN, PIK3CA, MET, KRAS, FBXW7, BRAF WES, ddPCR, TGS
Cohen et al. [132] 2016 32 CNV WES
Harris et al. [133] 2016 10 Aberrant chromosomal junctions RT-PCR
Piskorz et al. [134] 2016 18 TP53 mutation NGS
Parkinson et al. [135] 2016 40 TP53 mutation Digital PCR
Vanderstichele [136] 2017 57 CNV WGS
Phallen et al. [137] 2017 42 55 gene panel including TP53, KIT, ALK, APC, ERBB4 etc NGS (TEC-Seq) and ddPCR
Flanagan et al. [138] 2017 247 Methylation at CpG sites NGS
Widschwendter et al.
[139]
2017 151 Regions linked to COL23A1, C2CD4D and WNT6 TUC-BS & RRBS
Ratajska et al. [140] 2017 121 BRCA1/2 mutations NGS
Christie et al. [141] 2017 30 BRCA reversion mutation NGS
Weigelt et al. [116] 2017 19 BRCA reversion mutation NGS
Giannopoulou et al. [142] 2018 50 ESR1 RT-MSP
Du et al. [143] 2018 21 CNV and mutant genes including TP53, BRCA1, NOTCH2, DNMT3A
etc
NGS
Morikawa et al. [107] 2018 29 KRAS and PIK3CA ddPCR
Nakabayashi et al. [144] 2018 36 CNV WGS
Park et al. [109] 2018 4 TP53 ddPCR
Arend et al. [117] 2018 14 50 gene panel NGS
Lin et al. [145] 2019 97 BRCA reversion mutation, TP53 NGS
Kim et al. [110] 2019 102 TP53 mutant allele Sanger sequencing/Digital
PCR
Oikkonen et al. [118] 2019 12 ERBB2 amplification NGS
Iwahashi et al. [146] 2019 4 TP53, APC, BRCA1 and KRAS CAPP-seq
Noguchi et al. [119] 2020 10 gene mutation profiles and blood tumor mutation burden CAPP-seq
Han et al. [147] 2020 10 88 genes panel NGS
Alves et al. [148] 2020 11 Level qPCR
Abbreviations: NGS Next-generation sequencing, RT-PCR Reverse transcription polymerase chain reaction, dPCR droplet Polymerase chain reaction, qPCR Allele-
specific quantitative PCR, RT-MSP Real-Time methylation specific PCR, CNV Copy number variation, WGS Whole genome sequencing, WES Whole exome
sequencing, ddPCR Droplet digital PCR, TGS Targeted gene sequences, TAm-RSeq Targeted amplicon re-sequencing, RRBS Reduced representation bisulphite
sequencing, TUC-BS Targeted ultra-high coverage bisulphite sequencing, CAPP-seq Cancer Personalized Profiling by deep Sequencing
Sharbatoghli et al. Journal of Ovarian Research          (2020) 13:124 Page 6 of 12
with the clinically available drugs (PI3K/mTOR inhibi-
tor, PARP inhibitor, CDK2/4 inhibitor, CDK4/6 inhibi-
tor, HER2 inhibitor, trastuzumab, ERBB inhibitor,
lapatinib, and EGFR inhibitor) were detected. One
chemo resistant patient therapy has changed based on
the detection of ERBB2 amplification and ctDNA-guided
decision. These results can be considered as a proof of
using ctDNA concept to guide the clinical decisions dur-
ing the cycles of chemotherapy in ovarian cancers [118].
In addition, Noguchi et al. [119] compared the variant
allele frequency (VAF) of the measured ctDNA muta-
tions during neoadjuvant chemotherapy in 10 plasma
samples. In 5 out of 6 NAC-sensitive cases, the VAF of
non-synonymous somatic mutations (TP53, KCAN5, and
GJA8) decreased following NAC. Also, in two out of the
four NAC-resistant cases, the VAF increased in the non-
synonymous somatic mutations (KRAS, TRPS, and
TP53). The rate of TP53 mutation was significantly
higher in the resistant cases compared with the sensitive
cases. In addition, the blood tumor mutation burden sig-
nificantly decreased after the treatment in the sensitive
cases. These findings showed that, gene mutation can be
profiled and then monitored using ctDNA in ovarian
cancer patients during treatment. The Table 2 summa-
rizes the studies that used ctDNA analysis to monitor
treatment response in ovarian carcinoma. Lately, a
multi-center prospective study demonstrated that,
detectable ctDNA following treatment is associated with
a subsequent recurrence in ovarian cancer (trial,
NCT03691012). In this study, serial blood and tumor
samples were collected from 100-stage I-IV debulked
ovarian cancer patients under the platinum-based treat-
ment. Each patient was followed for more than a 6- to
8-month period for ctDNA (mutation) and CA125 ana-
lysis. After the completion of 6 cycles of chemotherapy,
analysis of plasma ctDNA has been shown to exhibit the
tumor-related alteration. Regarding the treatment
response monitoring in ovarian cancer, an ongoing pro-
spective multicenter trial (NCT03302884) was estab-
lished to assess ctDNA value for ovarian cancer
recurrence after the front-line treatment of chemother-
apy to profile the significant gene modifications before
the clinical diagnosis of disease relapse. In addition, the
assessment of the minimal residual disease through
plasma ctDNA in the ovarian cancer patients is currently
underway the prospective study (trial, NCT03614689).
In this study, match tumor DNA and longitudinal
plasma sample was collected from 100 ovarian cancer
patients before, during, and after the treatment. The cor-
relation between the clonal status of mutations and ther-
apy response, whether ctDNA detection would be used
to predict the ovarian cancer recurrence risk before and
after treatment, is an important point that was consid-
ered in this study. The immune checkpoint blockade
Table 3 Clinical trial studies related to ctDNA in ovarian cancer patients




Plasma ctDNA detection in diagnosis




Diagnostic Test: methylation markers
screening
Completed NCT03155451




Blood sampling Completed NCT01350908
Circulating tumor DNA guiding





• Drug: carboplatin + gemcitabine or
carboplatin + paclitaxel or carboplatin +
liposomal doxorubicin or liposomal
doxorubicin 4-weekly or topotecan or pacli-
taxel weekly
Recruiting NCT02822157
Assessment of the minimal residual
disease in ovarian cancer from





Circulating tumor DNA as a marker
of residual disease & response to




Diagnostic Test: Circulating tumour DNA
testing
Recruiting NCT03691012
Circulating tumor DNA as an early
marker of recurrence and treatment




biological sampling Recruiting NCT03302884
Study of the effects of




• Biological: Pembrolizumab Active, not
recruiting
NCT02644369
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(ICB) recently provides clinical benefits to a subset of
patients with ovarian cancer. Bratman et al. [120] have
started a prospective phase II clinical trial to assess
ctDNA in five distinct cohorts of patients including high
grade serous ovarian cancer patients with advanced solid
tumors treated with pembrolizumab (NCT02644369). At
baseline, 316 serial plasma samples at every three cycles
from 94 patients were obtained. These findings indicated
that serial ctDNA analysis could serve as a general moni-
toring strategy for patients treated with ICB and corre-
lates with their survival. The Table 3 summarizes the
clinical trial studies that used ctDNA analysis in ovarian
cancer management.
Conclusion and future perspective
In summary, ctDNA detection before treatment facili-
tates early detection and leads to appropriate treatment
decision-making based on patient stratification. Moni-
toring of the residual disease helps in prevention of re-
currence of the tumor. During the course of treatment,
regular monitoring of ctDNA can elucidate drug resist-
ance acquired from genetic alterations, which are always
present but not detectable by conventional approaches.
Therefore, genomic-based drug response prediction can
open new horizons in oncology to enable better cancer
patient’s management. In addition, a considerable num-
ber of clinical trials, mentioned in Table 3, highlight the
strong and novel roles of ctDNA in ovarian cancer man-
agement guidelines. Further efforts are required in the
future for standardization of analysis platforms and in-
corporation of liquid biopsies as a companion biomarker
in large-scale therapeutic trials.
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